Effects of early dexamethasone therapy on pulmonary fibrogenic mediators and respiratory mechanics in preterm infants.
Corticosteroid administration may prevent chronic lung disease in premature newborns, perhaps by modulating the synthesis of various cytokines, including those involved in fibrogenic processes. This study analyses the levels of three fibrogenic cytokines, namely vascular endothelial growth factor, transforming growth factor-beta 1 and basic fibroblast growth factor in tracheobronchial aspirate fluids collected from 20 premature newborns randomly assigned to the early dexamethasone group or to the control group. Furthermore, pulmonary function tests were performed on days 0 and 2 following the start of therapy. The results show that early corticosteroid administration reduces transforming growth factor-beta 1 and basic fibroblast growth factor levels, and abolishes the spontaneous vascular endothelial growth factor increase observed in untreated patients, concomitantly with significant improvement of dynamic lung compliance and shorter duration of the intubation period in the treated group of patients. Significant correlations were observed between the levels of transforming growth factor-beta 1 and vascular endothelial growth factor, indicating that the production of both these cytokines is coordinated. Finally, transforming growth factor-beta 1 ratios (day 2/day 0), representing early variations of the cytokine levels, were significantly different between treated and untreated subjects and correlated with the dynamic lung compliance ratios and the extubation day, suggesting that the downmodulation of some fibrogenic mediators may be involved in the mode of action of dexamethasone.
Vento
Giovanni
G
Department of Pediatrics, Division of Neonatology, Università Cattolica del S. Cuore, Rome, Italy. givento@tin.it
Matassa
Piero G
PG
Ameglio
Franco
F
Capoluongo
Ettore
E
Tortorolo
Luca
L
Romagnoli
Costantino
C
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood / Q000502:physiology; D003907:Dexamethasone / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D011658:Pulmonary Fibrosis / Q000517:prevention & control*; D015656:Respiratory Mechanics / Q000187:drug effects* / Q000502:physiology
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D003907:Dexamethasone